Compare Cassava Sciences Inc (FLNA) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Norwegian Cruise Line Holdings Ltd trades at $18.92 (market cap $8.59B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 179.9× Cassava Sciences Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | NCLH | |
|---|---|---|
Market Cap | $47.75M | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $26.94 |
52-Week Low | $0.87 | $14.79 |
Enterprise Value | -$34.93M | $23.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
NCLH trades at $19.09, up 2.91% today, with a bearish technical signal but recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding the $0.4115 estimate, and revenue growth has improved from $4.8B in 2022 to $9.83B in 2025. However, net income margin declined to 4.3% in 2025 from 9.6% in 2024, and high debt levels remain a concern with total liabilities of $18.54B against equity of $1.43B.
The outlook is mixed: analyst consensus is a Buy with a $20.73 price target, but risks include volatile fuel costs, macroeconomic pressures on travel demand, and execution of turnaround plans. The stock offers value with a P/E of 11.33, yet investor sentiment is cautious due to recent guidance cuts and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
